Drug Trial Radar · NCT06038396
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
48
Planned (sponsor's estimate)
Start
Aug 3, 2023
Primary completion
Feb 28, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open, multi-center, dose escalation and expansion phase I/II study. The Phase I study will explore the tolerability and safety of RC118 in combination with Toripalimab for the treatment of patients with Claudin 18.2-positive, locally advanced unresectable or metastatic malignant solid tumors, and to establish the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); The Phase II study will evaluate the efficacy and safety of RC118 in combination with Toripalimab or RC148 in patients with locally advanced or metastatic Gastric cancer/Gastro-esophageal junction cancer.
Conditions
- Advanced Solid Tumor
Interventions
RC118Drug
Dose A or dose B, Q2W
ToripalimabDrug
Fixed dose, Q3W
RC148Drug
Fixed dose, Q3W Other Names: RC148 injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase1: Dose limiting toxicity (DLT)Time frame: The first 3 weeks (21 days) after the start of dosing at each dose level
- Phase1/2: Adverse events (AEs)Time frame: [Time Frame: 15 months]
- Phase1: Maximum tolerated dose(MTD)Time frame: up to 12 months
- Phase1: Recommended Phase 2 Dose (RP2D)Time frame: up to 12 months
- Phase 2: Objective response rate (ORR)Time frame: 15 months
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital Fudan University
Shanghai, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Recruiting
Gansu Wuwei Tumour Hospital
Wuwei, Gansu, China · Recruiting
Meizhou People's Hospital
Meizhou, Guangdong, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Nanyang Central Hospital
Nanyang, Henan, China · Recruiting
Xinyang Central Hospital
Xinyang, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
Xuzhou Central Hospital
Xuzhou, Jiangsu, China · Recruiting
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Shandong, China · Recruiting
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Changzhi People's Hospital
Changzhi, Shanxi, China · Recruiting
West China Hospital Sichuan University
Chengdu, Sichuan, China · Recruiting
The Second People's Hospital of Neijiang
Neijiang, Sichuan, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.